Clinical trialNo phase (not a drug trial)Completed
The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors
The BurnAlong Pilot Study: Examining the Feasibility of a Virtual Group-based Physical Activity Intervention for Adolescent and Young Adult Cancer Survivors
- Outcome
- Finished, no results posted
- Phase
- No phase (not a drug trial)
- Status
- Completed
- Study type
- Interventional
- Start
- 25 July 2022
- Ended
- 15 June 2023
- Enrollment
- 8 participants
- Sites
- 1
- Primary outcomes
- Feasibility of BurnAlong
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 26 February 2025
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The purpose of this prospective, interventional, single-arm pilot study is to evaluate whether virtually delivered group-based physical activity is feasible for adolescent and young adult (AYA) cancer survivors. AYAs who were diagnosed with cancer and have completed cancer treatment will be recruited for this study. This study will enroll 20 participants in total and will last approximately 3 months.
Detailed description public domain (ClinicalTrials.gov)
This is a single-arm, prospective, interventional pilot study. Adolescent and young adult (AYA) survivors of cancer ages 18-39 (n=20) will engage in three months of virtually group physical activity (PA) delivered via BurnAlong, a wellness platform and online app. Participants will be asked to engage in a BurnAlong workout session with a partner (friend/spouse/child/fellow study participant) a minimum of three times a week for 3 months. Participants will also meet monthly with an exercise physiologist for a customized exercise session. Participants are allowed to engage in additional PA and non-PA sessions on BurnAlong as desired. Participants will also be asked to engage in a private social network discussions around key topics of interest for AYA communities with a focus on post-traumatic growth and positive psychology with a minimum of 2 post engagements a week for 3 months. Participants will complete surveys and physical assessments at baseline and at end of study. Participants also participate in a 1 hr qualitative exit interview about their well-being, participation experiences, and experience with using the BurnAlong platform.
Intervention public domain (ClinicalTrials.gov)
Behavioral: Virtual group based physical activity (BurnAlong) and Social Media Discussion Board. Participants will engage in two to three virtual physical activity sessions a week through the BurnAlong app for three months with a chosen partner and participate at least twice a week in the research team-mediated social media message board. Additionally, participants will be asked to participate in one live physical activity session per month with an exercise physiologist.
Arm public domain (ClinicalTrials.gov)
Virtual Group-Based Physical Activity (BurnAlong) and Discussion Board (experimental): Participants will be asked to complete a 12 week virtual physical activity program delivered by the BurnAlong app, participate in a discussion board, and engage in live physical activity sessions with an exercise physiologist.
Primary outcome public domain (ClinicalTrials.gov)
Feasibility of BurnAlong. Number of participants that adhere to a 3-month virtually delivered physical activity program via BurnAlong, group discussion boards, and a monthly live physical activity session with an exercise physiologist Time frame: 12 weeks.
Secondary outcome public domain (ClinicalTrials.gov)
Resting Heart Rate. Time frame: Measured at Baseline and at Week 12.
Secondary outcome public domain (ClinicalTrials.gov)
Sleep Duration. Time frame: Measured at Baseline and at Week 12.
Secondary outcome public domain (ClinicalTrials.gov)
Sleep Quality. Time frame: Measured at Baseline and at Week 12.
Secondary outcome public domain (ClinicalTrials.gov)
Patient-Reported Outcomes Measurement Information System (PROMIS)-29. Time frame: Measured at Baseline and at Week 12.
Secondary outcome public domain (ClinicalTrials.gov)
Post-Traumatic Growth Inventory (PTGI). Time frame: Measured at Baseline and at Week 12.
Secondary outcome public domain (ClinicalTrials.gov)
Health Action Process Approach Inventory (HAPA Inventory). Time frame: Measured at Baseline and at Week 12.
Eligibility public domain (ClinicalTrials.gov)
Inclusion Criteria: * Cancer (all types) diagnosis between the ages of 15-39 * Between the ages of 18-39 during study participation * At least 3 months post-active treatment completion * Answers "no" to all questions on the Physical Activity Readiness Questionnaire * Not currently meeting physical activity guidelines per leisure-time physical activity participation questionnaire * Access to and ability to use a computer, tablet or phone device with internet access * Ability to understand and read English * Written informed consent obtained from subject and ability for subject to comply with the requirements of the study Exclusion Criteria: * Hearing loss or vision impairment that would preclude the participant from accessing and using the app (use of hearing aids or visual aids is acceptable) based on self-report * Currently meeting physical activity guidelines (score of \>23 on Godin-Shephard Leisure-Time Physical Activity Questionnaire) * Currently pregnant, based on self-report * Patients with active treatment planned within the next 3 months. (Active treatment includes chemotherapy, biologic therapy, radiation therapy, surgery, and any combination.) Long-term hormonal/biologic treatments are acceptable except for AR-targeted therapies for prostate cancer. Participants with known metastatic disease, grade 3 or higher neuropathy, major surgery within 3 months of baseline visit, pregnancy of childbearing potential will be excluded.
Enrollment public domain (ClinicalTrials.gov)
Enrollment: 8 participants (actual).